Renal Cancer News and Research

RSS

New software programs improve the cancer biomarker identification process

caCORRECT and omniBioMarker programs earn silver-level compatibility certification from NIH/National Cancer Institute's cancer Bioinformatics Grid

19 Aug 2009

New immune therapy for kidney cancer tested

Researchers at The Cancer Institute of New Jersey (CINJ) have opened a clinical trial to evaluate whether the standard treatment for a common form of kidney cancer works better by itself or when combined with a certain type of blood cell that comes from a patient’s relative. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

14 Aug 2009

Combination of temsirolimus and bryostatin appears safe and active in metastatic kidney cancer

Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are less likely to respond to other targeted therapies.

31 May 2009

Seattle Genetics presents new data on antibody-drug conjugate

Seattle Genetics, Inc. has announced that data from its antibody-drug conjugate (ADC) programs, SGN-35 and SGN-75, were presented at the 2009 Annual Meeting of the American Association for Cancer Research (AACR) being held in Denver, CO. Preclinical data with SGN-35 further elucidate its mechanism of action and demonstrate its superior antitumor activity in lymphoma compared with non-targeted agents. In addition, data with SGN-75 indicate its therapeutic potential in multiple types of solid tumors.

22 Apr 2009

Discovery of new cancer gene

Researchers have identified a new cancer gene - one that is common to many cancers and affects the most basic regulation of our genes.

29 Mar 2009

$Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma$

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.

10 Dec 2008

Scientists pinpoint two new risk factors for Wilms tumour

Scientists at The Institute of Cancer Research have made significant progress in pinpointing two new risk factors associated with the most common childhood kidney cancer, known as Wilms tumour.

1 Dec 2008

Cancer drug bevacizumab linked to significantly increased risk of blood clots

An analysis of randomized controlled trials indicates that use of the cancer drug bevacizumab is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs), according to an article in the November 19 issue of JAMA, the Journal of the American Medical Association.

18 Nov 2008

Gene study sheds new light on lung cancer

A multi-institution team, funded by the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), today reported results of the largest effort to date to chart the genetic changes involved in the most common form of lung cancer, lung adenocarcinoma. The findings should help pave the way for more individualized approaches for detecting and treating the nation's leading cause of cancer deaths.

22 Oct 2008

VioQuest Pharmaceuticals issued new U.S. patent for Lenocta

VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.

26 Aug 2008

New model predicts whether patients will be free of renal cancer 12 years after initial treatment

A UT Southwestern Medical Center physician and other researchers have developed a unique statistical model that predicts the probability of a patient being cancer free 12 years after initial surgical treatment.

2 Jun 2008

Wyeth receives European approval for TORISEL

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the European Commission has approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.

27 Nov 2007

Health Discovery receives notice of allowance of U.S. patent application covering kernel selection methods

Health Discovery Corporation has announced that the U.S. Patent and Trademark Office has issued a notice of allowance of HDC's patent application covering methods for selection of kernels, i.e., functions or algorithms that are used to transform input data into a different configuration, known as "feature space", which allows for easier recognition of patterns within the data.

18 Oct 2007

Contact disorder makes cancer cells mobile

The loss of the protein VMP1 in cancer cells increases their tendency to detach from the initial tumor - the first step towards metastasis.

30 Aug 2007

Reactivating a critical gene lost in kidney cancer reduces tumor growth

Researchers at Mayo Clinic Jacksonville, have found that a key gene is often silenced in clear cell renal cell carcinoma, the most common type of kidney cancer, and when they restored that gene in human kidney cancer cells in culture and animal experiments, tumors stopped growing and many disappeared.

17 Aug 2007

Phase II study of TroVax vaccine in patients with metastatic colorectal cancer

A therapeutic cancer vaccine has shown effectiveness when given alongside chemotherapy to patients with metastatic colorectal cancer in a phase II trial, according to researchers at Oxford BioMedica (UK) Ltd.

2 Aug 2007

Study of therapeutic vaccine shows promise for metastatic colorectal cancer

1 Aug 2007

Researchers identify new combination therapy that promotes cancer cell death

Researchers at the University of Pennsylvania School of Medicine identified a combination therapy as a way to sensitize resistant human cancer cells to a treatment currently being tested in clinical trials They propose that the therapy may help to selectively eliminate cancer cells while leaving healthy cells intact, providing a cancer treatment with fewer side effects.

17 Jul 2007

Scientists take exciting approach for attacking cancers

A new study identifies a combination therapy that may sensitize human cancer cells to a promising treatment currently being used in clinical trials.

10 Jul 2007

Fatty fish provides significant protection against renal cancer

If you want to avoid cancer of the kidneys, a new major study from Karolinska Institutet in Sweden shows that eating salmon or other kinds of fatty fish a few times a month would be one good way to go about it.

21 Sep 2006